As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
On August 16-19, 2019, Shanghai Medicilon Inc. successfully organized The 5th Advanced Training Course for Non-clinical Safety Evaluation of Drugs for Study Director, which hosted by Drug Safety Evaluation Research Committee of China Pharmaceutical Association and National Institutes for Food and Drug Control. The training course lasted for 2 days and 13 experts were invited to give a speech. There were nearly 300 people to attend the training course.
Currently, China’s safety evaluation agencies have entered a period of rapid development, and the ranks and scale of personnel have been continuously expanded. Therefore, the new SD requires a new and better platform for exchange and development. In order to further promote the improvement of SD in the field of drug safety evaluation in China and promote the improvement of the overall capacity of China’s drug safety evaluation industry, the training course was based on the topic of “Non-Clinical Safety Evaluation of New Drug” and invited authoritative experts in the field of evaluation, experts in centers for drug evaluation, and senior SD in China to give a speech on approval strategy of new biological products and safety evaluation case analysis.